Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 USD | +5.62% | +19.52% | -51.44% |
Valuation
Fiscal Period: December | 2019 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 5.174 | 3.463 | - | - |
Enterprise Value (EV) 1 | 3.789 | 3.463 | 3.463 | 3.463 |
P/E ratio | -0.71 x | - | - | - |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | -715,778 x | - | - | - |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 8.26 | 2,240 | - | - |
Reference price 2 | 648.0 | 1.690 | 1.690 | 1.690 |
Announcement Date | 4/16/20 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA | -7.228 | - | - | - |
EBIT 1 | -7.259 | -7,846,208 | -10,287,422 | -12,755,616 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) | -6.826 | - | - | - |
Net income | -6.632 | - | - | - |
Net margin | - | - | - | - |
EPS | -912.0 | - | - | - |
Free Cash Flow | - | - | - | - |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 4/16/20 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2019 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT | -3.152 | - | - | - | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income | -3.028 | - | - | - | - |
Net margin | - | - | - | - | - |
EPS | -248.0 | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 4/16/20 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | 1.38 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | 3.02 | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 4/16/20 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CYTO Stock
- CYTO Stock
- Financials Altamira Therapeutics